Boston Scientific Corp. vs. Embecta Corp. Common Stock
Boston Scientific Corp. (BSX) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| BSX | EMBC | |
|---|---|---|
| Market Cap | $73.13 billion | $282.73 million |
| Revenue (TTM) | $21.00 billion | — |
| Net Income (TTM) | $3.67 billion | — |
BSX leads on 1 of 1 size & scale factors.
Valuation
| BSX | EMBC | |
|---|---|---|
| P/E Ratio | 20.43 | — |
| Price / Book | 2.91 | — |
| Price / Sales | 3.48 | — |
BSX and EMBC split the valuation factors evenly.
Profitability
| BSX | EMBC | |
|---|---|---|
| Net Margin | 17.47% | — |
| Return on Equity | 14.58% | — |
BSX and EMBC split the profitability factors evenly.
Dividend
| BSX | EMBC | |
|---|---|---|
| Dividend Yield | — | 0.80% |
BSX and EMBC split the dividend factors evenly.
Risk & Sentiment
| BSX | EMBC | |
|---|---|---|
| Short Interest | 0.72% | 2.25% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, EMBC overview, EMBC financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.